Altimmune Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results. Also, UBS Initiated Coverage on the Stock With a Buy Rating and Announced a Price Target of $26.
Altimmune Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results. Also, UBS Initiated Coverage on the Stock With a Buy Rating and Announced a Price Target of $26.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated